Education
About Us
Working with TipRanks
Follow Us
Pfizer (PFE)
NYSE:PFE
PFE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.95 - $31.54
Previous CloseN/A
Volume12.20M
Average Volume (3M)54.62M
Market Cap
$130.27B
Enterprise Value$198.11B
Total Cash (Recent Filing)$2.18B
Total Debt (Recent Filing)$44.17B
Price to Earnings (P/E)16.3
Beta0.32
Next Earnings
Apr 29, 2025EPS Estimate
0.71Last Dividend Ex-Date
Jan 24, 2025Dividend Yield7.36%
Share Statistics
EPS (TTM)1.41
Shares Outstanding5,671,454,600
10 Day Avg. Volume50,200,064
30 Day Avg. Volume54,622,219
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)N/A
Price to Sales (P/S)2.34
Price to Cash Flow (P/CF)5.50
P/FCF Ratio5.00
Enterprise Value/Market Cap1.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.20
Enterprise Value/Ebitda10.93
Forecast
1Y Price Target
$30.54Price Target Upside32.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Pfizer News
PremiumStock Analysis & Ideas
Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump
---
Bulls Say, Bears Say
Bulls Say
Business DevelopmentPfizer bought ADC leader Seagen for US$43bn, allowing Pfizer to develop ADCs, which boasts high efficacy and low adverse events.
Financial Performance2024 Q4 results beat expectations with effective cost cuts and better-than-expected covid products sales.
Bears Say
Patent ExpiriesInvestors remain concerned about the outlook for many of Pfizer's larger franchises due to upcoming patent expiries and competitive threats.
Regulatory ImpactPfizer expects Part D redesign to disproportionately impact higher-priced drugs, including Ibrance, Xtandi, Vyndaqel, and Xeljanz.
---
Ownership Overview
0.03% Insiders
17.93% Mutual Funds
12.19% Other Institutional Investors
46.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PFE FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest stock price was $22.95 and its highest was $31.54 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is $130.27B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is Apr 29, 2025 which is in 22 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Feb 04, 2025. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.472 by $0.158.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 7.36%. See more information on Pfizer dividends here
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.71.
How many shares outstanding does Pfizer have?
Pfizer has 5,671,454,600 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $0.63 in its last earnings report, beating expectations of $0.472. Following the earnings report the stock price went down -1.26%.
Which hedge fund is a major shareholder of Pfizer?
Currently, no hedge funds are holding shares in PFE
---
Pfizer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.54 (32.96% Upside)
$30.54 (32.96% Upside)
Blogger Sentiment
Bullish
PFE Sentiment 90%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 23.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $414.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Bullish
Bullish news 71%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.40%
12-Months-Change
Fundamentals
Return on Equity
9.05%
Trailing 12-Months
Asset Growth
-5.79%
Trailing 12-Months
Company Description
Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
---
PFE Company Deck
---
PFE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Pfizer demonstrated strong financial performance and strategic progress in 2024, with significant achievements in market leadership and pipeline advancements. While there are challenges with specific products and external factors such as the IRA, the overall sentiment is positive due to the robust execution and strategic positioning for future growth.Read More>---
PFE Revenue Breakdown
47.36% Primary Care
26.17% Specialty Care
24.54% Oncology
1.80% PFIZER CENTREONE
0.13% PFIZER IGNITE
---
PFE Stock 12 Month Forecast
Average Price Target
$30.54
▲(32.96% Upside)
Technical Analysis
Best Analysts Covering PFE
1 Year
1 Year Success Rate
26/36 ratings generated profit
1 Year Average Return
+4.71%
reiterated a buy rating 21 days ago
Copying Vamil Divan's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +4.71% per trade.
---